Turnstone is shifting resources to focus on clinical advancement of its selected tumor-infiltrating lymphocyte therapy as ...

Two biotechs set out for the public markets this week, with Upstream Bio raising $255 million for its inflammatory disease ...

Despite substantial variability in the presented data and no well-controlled trial, the FDA advisory committee voted in favor ...

The U.S. Department of Justice alleged that Teva violated the Anti-Kickback Statute and the False Claims Act. The payment is in addition to the criminal penalty paid by Teva USA under its deferred ...

Oditrasertib, which blocks the inflammatory RIPK1 protein, earlier this year also failed a Phase II trial in amyotrophic ...

With the regulatory approval for advanced breast cancer, Roche’s inavolisib is a potential challenger to Novartis’ PI3K ...

Vaccine biotech Gritstone bio is filing for bankruptcy while securing a stalking horse bid from an unnamed party, which the ...